Showing results (3301-3310 of 6,517) with videos related to
Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|January 18, 2022
Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancerYanze Yu, Han Zeng, Kaifeng Jin, et al.Cancer Immunology, Immunotherapy : CII|January 19, 2022
Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltrationSho Kawaguchi, Kenta Kawahara, Yukio Fujiwara, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1987
In vitro generation of tumour-specific lymphocyte reactivity to colonic carcinoma cells. Comparison with normal colonic mucosa cellsM Kuppner, S Wilkinson, E Casson, et al.Cancer Immunology, Immunotherapy : CII|January 9, 2022
Combination immunotherapy including OncoVEXmGMCSF creates a favorable tumor immune micro-environment in transgenic BRAF murine melanomaRobyn D Gartrell, Zoë Blake, Emanuelle M Rizk, et al.Cancer Immunology, Immunotherapy : CII|January 9, 2022
Hypoxia-inducible factor-1 alpha expression is induced by IL-2 via the PI3K/mTOR pathway in hypoxic NK cells and supports effector functions in NKL cells and ex vivo expanded NK cellsEmily Cluff, Carina C Magdaleno, Emyly Fernandez, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1987
The generation of tumor-specific in vivo protective immunity in the tumor mass from mice rendered tolerant to tumor antigensS Sano, Y Izumi, S Sugihara, et al.Cancer Immunology, Immunotherapy : CII|March 22, 2021
Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patientsTakeshi Ishikawa, Shinichi Kageyama, Yoshihiro Miyahara, et al.Cancer Immunology, Immunotherapy : CII|March 25, 2021
Activated B lymphocytes and tumor cell lysate as an effective cellular cancer vaccineKyp L Oxley, Brett M Hanson, Ashley N Zani, et al.Cancer Immunology, Immunotherapy : CII|June 18, 2011
Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4Dawn Holt, Xinrong Ma, Namita Kundu, et al.Cancer Immunology, Immunotherapy : CII|June 21, 2011
Immunotherapy of prostate cancer: should we be targeting stem cells and EMT?Naomi L Dunning, Stéphanie A Laversin, Amanda K Miles, et al.Pageof 652